Antibody Drug Conjugates Market Trends Report | Growth Forecasts to 2030

The antibody drug conjugates market size is projected to reach US$ 29,600.98 million by 2030 from US$ 7,793.43 million in 2022; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.

Market Insights and Analyst View:

Antibody-drug conjugates or ADCs are targeted medicines that help deliver chemotherapy agents to cancer cells. A chemotherapy substance is linked to a monoclonal antibody to facilitate their binding to a specific target expressed on cancer cell surfaces. Due to their accuracy and efficiency in killing cancer cells, ADCs have become one of the major hotspots for the R&D of anticancer drugs. Growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs drive the market growth. On the other hand, the high cost of ADC development and commercialization hinders the antibody drug conjugates market growth.

Growth Drivers:

Rising Incidence of Cancer Cases Propels Antibody Drug Conjugates Market Growth

The rising incidence of cancer is primarily bolstering the demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. The US, China, and India were among the countries with the highest number of cancer cases. GLOBOCAN also estimates that the cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. As per the World Health Organization (WHO) data published in February 2022, ~10 million people in the world have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. A list of common cancer cases reported worldwide in 2020 is provided below. 

New Cancer Cases Worldwide, in 2020

Source: World Health Organization, February 2020

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and those who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnoses in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Antibody Drug Conjugates Market: Strategic Insights

Market Size Value in	US$ 7,793.43 million in 2022
Market Size Value by	US$ 29,600.98 million by 2030
Growth rate	CAGR of 18.2% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The “Antibody Drug Conjugates Market” is segmented on the basis of technology, application, and distributional channel. By technology, the antibody drug conjugates market is bifurcated into cleavable and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share and is estimated to register the fastest CAGR during 2022–2030. The antibody drug conjugates market, by distribution channel, is segmented into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment held the largest market share, and the segment is estimated to record the fastest CAGR during 2022–2030.

Segmental Analysis:

By technology, the antibody–drug conjugates market is bifurcated into cleavable and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Non-cleavable linkers are further classified into thioether or maleimidocaproyl (MC) group linkers. Unlike cleavable linkers, non-cleavable ADCs are more dependent on the biology of target cells. ADCs developed using non-cleavable linker technology show decreased payload potency. This technology increases plasma stability and improves the therapeutic index of cancer treatment. Many studies have shown that non-cleavable linker technology used for the in vivo development of ADCs performs better than their cleavable counterparts. Also, non-cleavable linker technology provides a potentially larger therapeutic window than cleavable linkers, thus allowing ADC payload derivatives to kill target cells more effectively.

Antibody Drug Conjugates Market, by Technology – 2022 and 2030

Access Data

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and it is further estimated to register the fastest CAGR of 18.6% during 2022–2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

The antibody drug conjugates market, by distribution channel, is segmented into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment held the largest market share, and it is estimated to record the fastest CAGR of 18.5% during 2022–2030. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, and drug rehabilitation centers. Hospital pharmacies widely distribute prescribed drugs. ADCs are prescribed as advanced therapies for treating cancer, and thus, their dispensation requires more attention and care. As a result, ADCs are widely distributed through hospital pharmacies. In addition, hospital pharmacies have capacities to support the storage of extensive stocks.

Reimbursement on drugs purchased under healthcare plans is the primary benefit conferred by hospital pharmacies. They also have specialized stock-keeping and storage facilities even for investigational medications (which are being studied but have not yet been approved), which other community settings do not have. On the other hand, hospital pharmacies are not retail establishments and do not provide medications for non-hospitalized patients. They can purchase medicines directly from a manufacturer or supplier, eliminating a long distribution network.

Regional Analysis - Antibody Drug Conjugates Market:

Based on geography, the antibody drug conjugates market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the antibody drug conjugates market. Asia Pacific is expected to register the highest CAGR in the global antibody drug conjugates market during 2022–2030.

North America holds the largest share of the antibody drug conjugates market. The market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs; rising product approvals; growing awareness about ADCs; and a surging number of mergers, collaborations, and partnerships among market players. In addition, the significantly growing incidence of cancer is propelling the demand for ADCs. The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest number of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA’s data published in May 2021, 113 clinical trials were underway for 77 novel ADCs that targeted over 40 different targets.

The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market in this region is widely driven by collaborations between companies, rising incidence of cancer, and an increasing number of clinical trials. China is home to various innovators of ADCs that are exponentially contributing to the market growth. Players such as RemeGen Co., Ltd.; Zhejiang Medicine Co., Ltd.; and Jiangsu Hengrui Pharmaceuticals Company Ltd. are among the leaders in the ADCs market in the country. These companies are involved in developing ADCs to treat breast, gastric, and urothelial cancers. Companies have various products in the pipeline that are ready for launch in the market after the completion of clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin-targeting (MSLN-targeting) antibody-drug conjugate (ADC) or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has a Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different indications; the first combination is in phase III for the evaluation of its efficacy in treating urothelial cancer, while the second is in phase II for the examination of its capability to treat muscle-invasive bladder and gastric cancer.

Industry Developments and Future Opportunities – Antibody Drug Conjugates Market:

Various initiatives taken by leading players operating in the antibody drug conjugates market are listed below:

1. In June 2023, Innovent Biologics, Inc. and RemeGen Co., Ltd. entered into a clinical trial collaboration and supply agreement for the combination therapies of TYVYT (sintilimab injection) with RC88 [a novel mesothelin (MSLN)-targeting ADC] or RC108 [a novel c-Met-targeting ADC] as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent would provide clinical drug supplies of TYVYT (sintilimab injection) during the clinical trial collaboration. RemeGen would conduct Phase 1/2a clinical trials to study the safety and antitumor activity of the combination therapy of TYVYT (sintilimab injection) with RC88 or RC108 in Chinese patients with advanced solid tumors.
2. In July 2022, AstraZeneca signed a new global development and commercialization agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo’s proprietary ADC directed toward trophoblast cell-surface antigen 2 (TROP2), a potential new medicine for the treatment of multiple tumor types. DS-1062 is currently in the development phase for its activity against multiple tumors that commonly express TROP2, a cell-surface glycoprotein. TROP2 is overexpressed in almost all non-small cell lung cancers1 and breast cancers—2,3 tumor types, which have been a strategic focus for AstraZeneca for a long. This collaboration indicates AstraZeneca’s strategy to invest in ADC through the successful existing collaboration with Daiichi Sankyo.
3. In January 2022, Gilead Sciences, Inc. entered into two clinical trial collaborations and supply agreements with Merck (MSD outside of Canada and the US) to evaluate the combination of Gilead’s Trodelvy (sacituzumab govitecan-hziy) ADC targeting TROP-2 and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). As part of this collaboration, Merck is expected to sponsor a global Phase 3 clinical trial of Trodelvy combined with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.

Competitive Landscape and Key Companies - Antibody Drug Conjugates Market:

ADC Therapeutics SA; Pfizer Inc; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc; GSK Plc; Gilead Sciences Inc; AstraZeneca Plc; Astellas Pharma Inc; RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are the prominent antibody drug conjugates market companies. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.